Study findings provide valuable clinical information for metastatic castration-sensitive prostate cancer (mCSPC) prognosis in routine clinical practice.

A new form of focal therapy for prostate cancer has made its way to the Natural State, set to be offered by the University of ...

A Nigerian researcher, Dr Jerry Adeyemo, has identified alternative therapies that could help in the treatment of prostate ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease who are eligible to receive the drug.

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which ...

A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was ...

Assessing prostate-specific antigen levels for 3 months after radical prostatectomy may help minimize overtreatment, ...

Neuroendocrine prostate cancer (NEPC) is the most aggressive form of prostate cancer, responsible for up to 20% of therapy-resistant cases and associated with rapid disease progression. It is ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

Researchers have unlocked a powerful new way to fight solid tumors using smart immune cells that stay active longer and hit ...

Prostox test is used to predict radiation side effects in prostate cancer patients based on their unique genetic profiles.